480 related articles for article (PubMed ID: 29741925)
1. Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice.
Rautiainen P; Tirkkonen H; Laatikainen T
Diabetes Technol Ther; 2018 May; 20(5):363-369. PubMed ID: 29741925
[TBL] [Abstract][Full Text] [Related]
2. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
[TBL] [Abstract][Full Text] [Related]
3. Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus.
Abalı S; Turan S; Atay Z; Güran T; Haliloğlu B; Bereket A
Pediatr Diabetes; 2015 Aug; 16(5):361-6. PubMed ID: 25039448
[TBL] [Abstract][Full Text] [Related]
4. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
[TBL] [Abstract][Full Text] [Related]
5. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
6. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
[TBL] [Abstract][Full Text] [Related]
7. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
8. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
Pala L; Dicembrini I; Mannucci E
Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
[TBL] [Abstract][Full Text] [Related]
9. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of continuous subcutaneous insulin infusion and daily supplemental insulin glargine injection in children with type 1 diabetes.
Alemzadeh R; Parton EA; Holzum MK
Diabetes Technol Ther; 2009 Aug; 11(8):481-6. PubMed ID: 19698060
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
[TBL] [Abstract][Full Text] [Related]
12. Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine.
Fahlén M; Eliasson B; Odén A
Diabet Med; 2005 Apr; 22(4):382-6. PubMed ID: 15787660
[TBL] [Abstract][Full Text] [Related]
13. Basal insulin substitution with glargine or continuous subcutaneous insulin infusion in adult type 1 diabetes patients-a randomized controlled trial.
Bragd J; von Döbeln A; Lins PE; Adamson U; Bergström J; Oskarsson P
Diabetes Technol Ther; 2010 Sep; 12(9):689-93. PubMed ID: 20687863
[TBL] [Abstract][Full Text] [Related]
14. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.
Doyle EA; Weinzimer SA; Steffen AT; Ahern JA; Vincent M; Tamborlane WV
Diabetes Care; 2004 Jul; 27(7):1554-8. PubMed ID: 15220227
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
Lin S; Chen M; Chen W; Lin K; Mu P; Zhu B; Xu W; Wang M; Weng J; Zeng L
J Diabetes Res; 2018; 2018():2791584. PubMed ID: 30420969
[TBL] [Abstract][Full Text] [Related]
16. Continuous subcutaneous insulin infusion versus multiple daily injection therapy in pregnant women with type 1 diabetes.
Gong Y; Wei T; Liu Y; Wang J; Yan J; Yang D; Luo S; Weng J; Zheng X
J Diabetes; 2024 May; 16(5):e13558. PubMed ID: 38664886
[TBL] [Abstract][Full Text] [Related]
17. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
[TBL] [Abstract][Full Text] [Related]
18. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes.
Pickup JC; Renard E
Diabetes Care; 2008 Feb; 31 Suppl 2():S140-5. PubMed ID: 18227475
[TBL] [Abstract][Full Text] [Related]
19. A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN).
Tsujino D; Nishimura R; Morimoto A; Tajima N; Utsunomiya K
Diabetes Technol Ther; 2012 Jul; 14(7):596-601. PubMed ID: 22775404
[TBL] [Abstract][Full Text] [Related]
20. Treatment Modality-Dependent Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes: Danish Adult Diabetes Database Study.
Hoshina S; Andersen GS; Jørgensen ME; Ridderstråle M; Vistisen D; Andersen HU
Diabetes Technol Ther; 2018 Mar; 20(3):229-234. PubMed ID: 29437465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
